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Abstract: Recently, a Salmonella Typhi isolate producing CTX-M-15 extended spectrum β-lactamase
(ESBL) and with decreased ciprofloxacin susceptibility was isolated in the Democratic Republic of the
Congo. We have selected bacteriophages that show strong lytic activity against this isolate and have
potential for phage-based treatment of S. Typhi, and Salmonella in general.
Keywords: typhoid fever; Salmonella Typhi; extended-spectrum beta lactamases (ESBL); Democratic
Republic of the Congo; bacteriophages
Viruses 2018, 10, 172; doi:10.3390/v10040172 www.mdpi.com/journal/viruses
Viruses 2018, 10, 172 2 of 9
Although effective oral antibiotics used to be readily available, today antimicrobial resistance
in Salmonella Typhi is becoming an increasingly serious public health concern, especially in low- and
middle-income countries (LMICs). Resistance to all first-line antimicrobials used in the treatment of
S. Typhi infections emerged sequentially, leading to multidrug resistance (MDR) in the 1990s, and more
recently, high levels of fluoroquinolone resistance in South Asia [1]. Recent data from the Typhoid Fever
Surveillance in Africa Program (TSAP) indicates that the incidence rate for typhoid fever in Africa has
been underestimated and is equal to, or even greater than, incidences reported in Asia [2]. Therefore,
extended spectrum β-lactamase (ESBL) producing Enterobacteriaceae and fluoroquinolone resistant
Salmonellae were included in the high-priority tier of the recent WHO priority list of antibiotic-resistant
bacteria [3].
In general, it is acknowledged that global antimicrobial resistance (AMR) poses a fundamental
long-term threat to human health, the production of food, and sustainable development. Based
on scenarios of rising drug resistance for only six pathogens, experts estimated that by 2050, up to
10 million people could die every year from the effects of AMR and it could also impose an economic
burden of US$100 trillion [4]. Recently, the UN committed to supporting the development of new
antimicrobial agents and therapies [5].
Phage therapy is one of the promising “new” treatments that has been increasingly featured [6].
Bacteriophages (phages in short) are naturally occurring viruses of bacteria. Since the early phases
of evolution, phages have controlled bacteria on our planet. In the early twentieth century, humans
discovered them and immediately applied them to medicine. This was especially true in the former
Soviet Union, where the use of phages continued after the advent of commercial antibiotics [7].
They can be selected to kill only certain bacteria of concern (e.g., bacteria causing infectious diseases)
while leaving non-pathogenic bacteria and mammalian cells unharmed. As such, they can be
effective against antibiotic-resistant bacteria and, in contrast to broad-spectrum antibiotics, spare
the gut microbiota, which could particularly benefit malnourished and immunocompromised patients.
In addition, phages can be easily isolated from environmental sources such as river or sewage water,
using basic tools available in LMICs [8].
In 2017, a case of typhoid fever in a six-year-old boy in the Democratic Republic of the Congo
(DRC) caused by an S. Typhi isolate producing CTX-M-15 extended spectrum β-lactamase (ESBL)
and showing decreased ciprofloxacin susceptibility, was reported [9]. CTX-M-15 is part of the M1
group that includes six plasmid-mediated enzymes [10]. This isolate, named Typhi 10040_15, was
sent to the Eliava Institute of Bacteriophage, Microbiology & Virology (EIBMV) in Tbilisi (Georgia)
to determine phage susceptibility. The 14 Salmonella phage clones of the Eliava R&D collection and
five batches of the commercial phage cocktail “INTESTI phage” were tested. Phage screening against
this S. Typhi strain was performed at the EIBMV’s BSL-2 Plus laboratory, meeting the required safety
requirements. The fourteen phage clones were isolated from the river Mtkvari in Tbilisi, from the
Black Sea (Batumi) and from the Tbilisi sewage water supply system in the period 2013–2017 (Table 1).
The five tested INTESTI phage batches were #M 067 (produced in July 2017), #M2 901 (November
2017), #84 of (February 2017), #82 (January 2017), and #78 (December 2016).
As in many other pathogenic bacteria, temperate phages contribute to virulence in Salmonella enterica
through the acquisition and exchange of virulence factors [11]. To assert the strictly lytic nature of
these phages, high-resolution genome maps of 12 of the 14 individual phages were obtained using
nanopore sequencing [12]. A pooled library consisting of barcoded genomic DNA of the phages was
prepared using native barcodes and the 1D ligation kit from Oxford Nanopore Technology (ONT).
The result was then sequenced on a MinION device, equipped with an R9.4 flowcell. For the data analysis,
Albacore v2.1 (ONT, Oxford, UK) was used for base-calling the reads, followed by porechop v0.2.1
(https://github.com/rrwick/Porechop) in order to remove barcode sequences. Genome map assembly
was performed with Canu v1.6 (https://github.com/marbl/canu) [13]. All the assembled genomes
were subsequently processed with Racon v0.5 for better consensus sequences [14], and nanopolish v0.8.3
(https://github.com/jts/nanopolish) for higher accuracy of base-called nucleotides in the sequences.
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Considering the intrinsic properties of nanopore sequencing, together with the run coverage (30× to 60×),
we define these assemblies as high-resolution phage maps, rather than fully accurate genome sequences.
Known homologous phage isolates were first located using the blastn tool on the NCBI nucleotide
database [15]. For each of our new isolates, the closest match (highlighted in bold) in terms of query
coverage and identity was identified and the corresponding genome downloaded. The genomic distance
between all the pairs of phages was calculated using Mash [16] and the resulting distance matrix was used
to build the clustering tree (Figure 1) with the hclust function found in the R stats package [17]. No known
toxin genes were present and the genomes did not contain recognizable integrase genes, corroborating
the lytic nature of these bacteriophages. Sequences were submitted to GenBank (Accession numbers:
MG969404-15).
Figure 1. Clustering tree based on the genomic distance matrix generated for the Salmonella phages
from the Eliava R&D collection and their closest matches (in bold) in the NCBI database. No genome
maps were obtained for phages GE_vB_N3 (Siphovirus) and GE_vB_M1 (Podovirus).
Morphological analysis using Transmission Electron Microscopy (TEM) of the phage clones
confirmed their general classification (Table 1). Purification and staining of the samples was performed
according to Hans-W. Ackermann [18] and preparations were examined with JEOL-JEM-1400 TEM
(Figure 2). Phages belonged to the families of the Siphoviridae (n = 6), Myoviridae (n = 6) and Podoviridae
(n = 2). The genome map-based grouping allowed us to further assign these phage clones to individual
phage species/genera, as indicated in Table 1.
The host range of the phages was assessed by screening their lytic activity and using the
spot test against 118 clinical and 121 veterinary Salmonella. spp. isolates from Georgia (20),
Armenia (71), Germany (7), and Ireland (141). These isolates belonged to the following serotypes:
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S. Typhimurium (95), S. Enteritidis (45), S. Dublin (23), S. Anatum (11), S. Infantis (9), S. Newport (8),
S. Derbey (8), S. Bredney (5), S. Branderburg (3), S. Germinara (2), S. Uganda (2), S. Senftenberg (2),
S. Kentucky (2), S. Reading (2), S. Parat. B (2), S. Java (1), S. Bareilly (1), S. Virchow (1), S. Goldcost (1),
S. Kottbus (1), S. Agona (1), and S. Poona (1). Thirteen isolates were not attributed to any known
serotypes. Two hundred microlitres of S. enterica mid-log phase cultures were mixed with 5 mL of
lukewarm 0.6% Lysogeny Broth (LB, Merck, Darmstadt, Germany) agar and overlaid on LB agar plates.
The LB broth consisted of 10 g peptone from casein, 5 g yeast extract and 10 g NaCl in 1 L of deionized
water. After the plates had cooled, 5 µL of the phage clones, with a titer of 107 plaque forming units
(pfu)/mL was spotted on the lawn. Drops were air-dried and plates were incubated for 18 h at 37 ◦C.
After the incubation, the plates were checked for zones of clearance resulting from phage activity [19].
The host range of the phages varied from 12 to 81% of the S. enterica strains (Table 1). It should be noted
that the spot test is usually performed to determine bacterial susceptibility and host range using as
many bacterial strains as possible because this method is simple, quick and inexpensive. A significant
part of bacterial cell killing can be due to “lysis from without”, i.e., the destruction of bacterial cells
by the adherence of a sufficiently high number of phages to the bacterial cell, and the destruction of
an essential cell wall structure by an extracellular lytic enzyme with subsequent lysis, but without
phage replication.
Figure 2. Tansmission electron micrographs of phages in left->right, top->bottom order: GE_vB_N3,
GE_vB_N5, GE_vB_N8, GE_vB_MG, GE_vB_BS, GE_vB_B1, GE_vB_B3, GE_vB_NS7, GE_vB_M4,
GE_vB_M5, GE_vB_TR, GE_vB_7A, GE_vB_M1. Scale bar, 100 nm.
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The lytic activity of the 14 phage clones and of the five INTESTI phage batches against the Typhi
10040_15 isolate from the DRC was evaluated using the spot test and the streak method. For the streak
method, mid-log phase S. Typhi was plated as a single line on an agar plate, air dried and 5 µL of single
phage clones (titer 107 pfu/mL) was dropped on the bacterial line. Drops were air-dried and plates
were incubated for 18 h at 37 ◦C. After incubation, plates were checked for zones of clearance resulting
from phage activity [20]. Twelve out of 14 phage clones and three out of five batches of the commercial
preparation INTESTI phage formed clear lysis zones on the CTX-M-15, producing an S. Typhi strain
from the DRC. This occurred in the streak method, as well as in the spot test. The batches #M 067
and #M2 901 showed the strongest lytic activity with clear confluent zones, while batch #84 only
developed weakly distinguishable discrete lytic zones. Only two phage clones, phage GE_vB_MG
(Myoviridae, Vequintavirinae, Se1virus, Salmonella virus SE1) and phage GE_vB_TR, a potential lysogenic
phage (Podoviridae, P22virus), showed no activity against the Typhi 10040_15 isolate (Table 1).
To assess the ability of phages to multiply inside the bacterial cells (creating phage plaques), the
activity of the 14 phage clones (but not the INTESTI phage batches) was tested using the method of
Gratia. A 200 µL mid-log phase culture of S. Typhi and 1 mL of a ten-fold diluted phage suspension,
ranging from 106 to 1010 pfu/mL, were mixed with 5 mL of lukewarm 0.6% LB agar and overlaid on
LB agar. Plates were incubated at 37 ◦C for 18 h and checked for plaque formation [21]. All phage
clones, with the exception of three (GE_vB_N8, GE_vB_HIL and GE_vB_M1), were found to form
plaques on the bacterial lawn (Table 1).
Finally, to confirm the ability of the phages to lyse the DRC S. Typhi strain in aqueous solutions,
the lytic activity of the 14 phage clones was determined using Appelman’s method. The 14 phage
clones were diluted ten-fold to range from 106 to 1010 pfu/mL in 5 mL of LB broth and inoculated
with 150 µL (109 cfu/mL) overnight S. Typhi culture. Mixtures were incubated at 37 ◦C without
shaking and the turbidity of the samples was checked visually after 6, 18 and 24 h. As reference and
control samples, phage-free bacterial culture and diluted phages without bacteria were tested under
the same conditions [22]. Ten phage clones showed activity at different time points and concentrations,
five of which showed the ability to lyse the CTX-M-15 producing S. Typhi isolate without forming
phage-resistant mutants after 24 h of incubation, which is indicative of their inherent ability to limit
the growth of phage-resistant mutants during phage therapy: GE_vB_N3, GE_vB_N5, GE_vB_N8,
GE_vB_NS7 and GE_vB_HIL (Table 1). It should be noted that phages GE_vB_MG and GE_vB_TR
are not active according to the spot and the streak tests, while still forming plaques according to
the method of Gratia. The difference between these two methods is not that uncommon and could,
for example, be caused by differences between phages’ “lysis from without” (accentuated in the spot
test) and phage infection, or “lysis from within” (accentuated in the Gratia test) capabilities. In other
words, some phages could be less efficient in adhering to, and entering bacterial cells, while being very
efficient once the normal lytic cycle is initiated. The spot test and the streak method are rapid ways to
check whether a phage can infect a bacterium by trickling small droplets of the phage suspensions
to be tested on a plate prepared with a bacterial isolate. Limitations of these tests compared with the
Gratia and Appelmans methods are that clear zones on the bacterial lawn (a positive test), may be
the result of abortive infection or lysis from without, both forming clear zones without new phages
being produced.
The evolution of bacterial resistance to phages is often observed in vitro. Phages have evolved
multiple strategies to overcome the antiviral mechanisms they encounter when infecting bacterial
cells [23]. In experimental settings, phage-resistant bacteria emerged rapidly, but often at significant
fitness costs, shown by the reduced growth rate in the absence of phages [24]. The in vivo evolution
of bacterial resistance to phages in human clinical practice, however, was poorly documented until
now. It has been suggested that phages could be combined with antibiotics to improve phage activity
(synergy) [25].
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Table 1. Characteristics of 14 Salmonella phages from the Eliava collection tested on the Typhi 10040_15_DRC_2015 isolate from the Democratic Republic of the Congo
(DRC).
Nr Name
GenBank
Accession
Numbers
Source Isolation
Year
Host Strain Family
Homology to
Other Phages
Host Range (%) *All
Serovars/S. Enteritidis/S.
Typhimurium/S. Dublin
(Total Number of Tested
Isolates)
Lytic Activity on the Typhi 10040_15_DRC_2015 Isolate
Streak
Method
Spot
Test
Gratia’s
Method
Appelmans’ Method
Titer
(pfu/mL) Dilution 6 h 18 h 24 h
001 GE_vB_N3 ND Mtkvari
river water
2013 S. Enteritidis 3 Siphoviridae ND 78/98/73/87 (239) + + +
109 −1 − − +
108 −2 − − +
107 −3 − + +
002 GE_vB_N5 MG969412 Mtkvari
river water
2013 S. Enteritidis 3 Siphoviridae
E. coli T5 strain
ATCC
11303-B5
45/80/25/74 (239) + + +
108 −1 − + +
107 −2 − + +
106 −3 − + +
003 GE_vB_N8 MG969413 Mtkvari
river water
2013 S. Enteritidis 3 Siphoviridae phage SPC35 65/84/67/78 (239) + + −
109 −1 − − +
108 −2 − − +
107 −3 − + +
004 GE_vB_MG MG969411
Tbilisi
sewage
water
2013 S. Enteritidis 3 Myoviridae S. phagePVP-SE1
47/49/59/43 (239) − − +
109 −1 − − −
108 −2 − − −
107 −3 − − −
005 GE_vB_BS MG969407 Black Sea
water
2013 S. Typhimurium 4 Myoviridae
S SPT-1, partial
genome 81/96/93/83 (239) + + +
1010 −1 + − −
109 −2 + − −
108 −3 + − −
006 GE_vB_B1 MG969405 Mtkvari
river water
2013 S. Typhimurium 6 Myoviridae S. phage
Mushroom
80/93/83/87 (239) + + +
109 −1 + − −
108 −2 + − −
107 −3 + − −
007 GE_vB_B3 MG969406 Mtkvari
river water
2013 S. Typhimurium 6 Myoviridae S. phage
Mushroom
81/98/73/87 (239) + + +
109 −1 + − −
108 −2 + − −
107 −3 + − −
008 GE_vB_NS7 MG969414 Raw cow
milk
2015 S. Typhimurium 6 Myoviridae S. phage
Mushroom
75/91/81/78 (239) + + +
109 −1 + − −
108 −2 − + −
107 −3 − + +
009 GE_vB_M4 MG969409 Black Sea
water
2016 S. Enteritidis 232 Siphoviridae
S. phage
vB_SenS-Ent3
23/64/18/22 (218) + + +
1010 −1 + − −
109 −2 + − −
108 −3 − − −
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Table 1. Cont.
Nr Name
GenBank
Accession
Numbers
Source Isolation
Year
Host Strain Family
Homology to
Other Phages
Host Range (%) *All
Serovars/S. Enteritidis/S.
Typhimurium/S. Dublin
(Total Number of Tested
Isolates)
Lytic Activity on the Typhi 10040_15_DRC_2015 Isolate
Streak
Method
Spot
Test
Gratia’s
Method
Appelmans’ Method
Titer
(pfu/mL) Dilution 6 h 18 h 24 h
010 GE_vB_M5 MG969410 Black Sea
water
2016 S. Enteritidis 407 Siphoviridae
S. phage
vB_SenS-Ent3
33/66/26/61 (218) + + +
108 −1 + − −
107 −2 + − −
106 −3 + − −
011 GE_vB_TR MG969415 Mtkvari
river water
2017 S. Typhimurium
641
Podoviridae S. phage BTP1 40/90/28/59 (141) − − +
109 −1 − − −
108 −2 − − −
107 −3 − − −
012 GE_vB_HIL MG969408 Mtkvari
river water
2017 S. Enteritidis 765 Siphoviridae
S. phage
vB_SenS-Ent3
58/81/75/77 (141) + + −
1010 −1 + − −
109 −2 − − −
108 −3 − + +
013 GE_vB_7A MG969404 Mtkvari
river water
2017 S. Typhimurium
1328
Myoviridae S. phage
BPS15Q2 37/62/28/23 (141) + + +
108 −1 − − −
107 −2 − − −
106 −3 − − −
014 GE_vB_M1 ND Black Sea
water
2016 S. Enteritidis 104 Podoviridae ND 12/20/19/0 (77) + + −
109 −1 − − −
108 −2 − − −
107 −3 − − −
* The host range of the phages was determined for the total Salmonella strain collection (all serovars), with the total number of strains indicated between brackets, and for the three main
serovars (S. Enteritidis/S. Typhimurium/S. Dublin) separately. ND, not done; “+”, phage lytic activity; “−”, no phage lytic activity; S. phage: Salmonella phage.
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In conclusion, in a short time frame (two days), at least five phage clones from the Eliava collection
were found to exhibit excellent in vitro lytic activity against the ESBL, producing an S. Typhi isolate
from the DRC. Phages can be considered a potential additional tool for the treatment of MDR Salmonella
infections and a (food) decontamination agent. Antimicrobials that address foodborne diseases are
particularly important for LMICs as many of them lack reliable cold chain infrastructure and adequate
hygiene practices [8]. In Western countries, several phage products are currently approved for the
control of food pathogens, including Salmonella. In addition, phage preparations can be developed and
produced faster and cheaper than conventional drugs. They can also be (freeze-)dried [26] so that they
require no refrigeration [8].
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